Axsome Therapeutics is a biopharmaceutical company that develops and commercializes treatments for central nervous system disorders. Its approved products include Auvelity for major depression, Sunosi for excessive daytime sleepiness related to narcolepsy or sleep apnea, and Symbravo for acute migraine treatment. The company's pipeline includes investigational candidates in late-stage development for conditions such as Alzheimer's-related agitation, smoking cessation, narcolepsy, fibromyalgia, and attention deficit hyperactivity disorder.
1Y: 143.52 (+5.7%) · range 134.93–255.17
entry readiness 83 · STRONG SETUP · exit proximity 0
Value area 197.08–254.70 · 97% of 120d volume overhead · heavy supply
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.967 | Nov 3, 2026 |
| trader-sentiment | 0.185 | Nov 2, 2026 |
Not yet labeled — the study prices these as positions mature.